ORTEC
16.1.2024 15:31:30 CET | Business Wire | Press release
ORTEC, a global provider of decision support software and data science capabilities, is pleased to announce a partnership with investment firm Battery Ventures to accelerate its growth ambitions. This strategic partnership, including a significant investment by Battery, marks a key moment in ORTEC’s existence and positions the company to increase its impact on customers and in core markets globally. With this partnership, ORTEC will be able to further strengthen its leadership position in the US and Europe in the field of supply chain, workforce-management and data science & consulting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116805637/en/
Michael van Duijn (ORTEC CEO) and Zak Ewen (Partner Battery Ventures) (Photo: Business Wire)
Improving the world through data and mathematics
The ORTEC journey started in the early 1980s, when a few passionate Dutch students wanted to show the world the value of mathematics by creating long-term sustainable growth for organizations and society. Specifically, the company’s initial consulting business helped customers leverage data and mathematical models to solve operational problems. Over time, the company developed commercial products that help large enterprises address complex logistical challenges such as last-mile fleet dispatch and route planning; pallet-load planning and optimization; and advanced workforce scheduling and resource planning.
Now, more than 40 years later, ORTEC delivers solutions to over 1,200 customers worldwide to improve business results and make a positive impact on the world. Customers include ASML, Heineken, Coca-Cola Enterprises, Procter & Gamble, Shell, Waitrose, Albert Heijn, G4S, Sodexo and Tesco.
In partnership with Battery, going forward, ORTEC will offer products and services through three new divisions that focus on logistics and routing solutions, workforce-management solutions, and data science and consulting. Battery, which was founded in 1983, is a longtime, global software investor that has made more than 500 investments over the last four decades.
“We are very pleased that Battery Ventures joins ORTEC as a strategic partner. With their knowledge, experience, and network, we can further drive innovation, expand our market reach and create additional impact for our customers,” said Michael van Duijn, ORTEC’s chief executive. “I am proud of the great company we are today and the amazing group of talented employees that create impact for our customers day in and day out. It makes me excited that with this partnership, we have the ingredients to make a more positive impact on the world.”
Shared commitment to long-term growth
The agreement between ORTEC and Battery Ventures highlights a shared commitment to drive innovation, deliver exceptional value to customers, and achieve long-term impact growth. Both parties are confident that the partnership will pave the way for ORTEC to expand its strong position as a leading provider of optimization technology built to solve complex operational challenges in an increasingly data-driven world.
“We’ve gotten to know ORTEC and its founding team over a period of more than 10 years, and during that time we’ve watched the business transform from a consulting-led business into a commercial software company serving the world’s most sophisticated and complex enterprises,” said Zak Ewen, a Battery partner based in London, who joins ORTEC’s board. “Now we’re excited to formally partner with Michael, Aart, Gerrit and the rest of the team to further accelerate the company’s mission.”
Moving forward, ORTEC founders Aart van Beuzekom and Gerrit Timmer remain part of the board and will continue to take care of ORTEC and its future.
About ORTEC
For more than 40 years ORTEC has been supporting many of the world’s best-run organizations to make better data-driven decisions. Our decision support software and data science capabilities enable our customers to improve their business results and make a positive impact on the world. With our 1,000 employees across 13 countries, we help over 1,200 leading customers worldwide to make better choices in an ever-changing environment. Discover more at www.ortec.com.
About Battery Ventures
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116805637/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom